Ten-years data of the first European clinical experience with once-daily tacrolimus extended release formulation in renal transplant recipients

Marielle ACJ Gelens, Johannes P Van Hooff, Monique J.M. Mullens, Maarten HL Christiaans


Background: Clinical data about long-term use of tacrolimus QD are lacking.

Methods: Ten-years data were collected from 37 renal transplant recipients participating in a Tacrolimus BID (Prograf®) to QD (Advagraf®) conversion study. They were converted at a median of 4.1 years post-transplant (range 1.5-11.4) with a stable renal function (serum creatinine < 264 umol/L) on tacrolimus based immunosuppression (monotherapy 29, dual therapy 8). Thirty were first transplants and original renal disease was in 16 immunologic, 14 non-immunologic, and 7 unknown. Eleven received their kidney from a living donor.

Results: There were no acute rejections. Thirty-four recipients were on tacrolimus QD up to end of follow-up. Three patients were censored at 2, 3, and 4 years post-conversion. Actuarial 5- and 10-year patient survival rates were 92% and 85%, respectively. Five patients died with a functioning graft 1.2 - 9.2 years post-conversion. Actuarial 5- and 10-year death-censored graft survival rates were 100% and 83%, respectively. The 5 graft losses occurred at 8.2 - 9.0 years post-conversion (3 due to recurrence IgA nephropathy, chronic rejection, and renal failure after cardiac surgery). Serum creatinine was 128 umol/L (range 64-180) at conversion and 141 umol/L (range 66-304) at 10 years. All patients with a non-immunologic cause of renal failure had a stable creatinine, while the 8 patients with an increase in serum creatinine >20% had an immunological or unknown cause of renal failure.

Conclusion: Patients on tacrolimus QD have excellent 10-year renal function, patient - and graft survival.


Tacrolimus once-daily, renal transplant, long term graft survival, renal function

Full Text:



Kramer BK, Charpentier B, Backmann et al. Tacrolimus once daily (Advagraf) versus twice daily (Prograf) in de novo renal transplantation: a randomized phase III study. Am J Transpl 2010; 10: 2632.

van Hooff JP ,Alloway RR, Trunecka P, Mourad M. Four year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transpl 2011; 25: E1-E2.

van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit 2012; 34: 46.

Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013; 95: 333.

Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation 2011; 92: 648.

Stifft F, Stolk LML, Undre N, van Hooff JP, Christiaans MHL. Lower Variability in 24 hour Exposure during Once-daily compared to Twice-daily Tacrolimus formulation in Kidney Transplantation. Transplantation 2014; 97: 775

Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757.

Whalen H, Glen J, Stevens K, Geddes C, Clancy M. High-Intrapatient Tacrolimus variability in a low-dose tacrolimus regimen predicts worse long-term outcomes after renal transplantation; WTC 2014 San Francisco. Abstract 2923.

Clayton P, McDonald S, and Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transpl. 2011; 11: 1645

Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 1032.

Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68: 635.

van Duijnhoven EM ,Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003; 16: 721

DOI: http://dx.doi.org/10.18103/imr.v3i5.478


  • There are currently no refbacks.
Copyright 2016. All rights reserved.